Cargando…

DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia

BACKGROUND: Despite its inconsistent response rate, decitabine, a demethylating agent, is often used as a non-intensive alternative therapeutic agent for acute myeloid leukemia (AML). It has been reported that relapsed/refractory AML patients with t(8;21) translocation achieved better clinical outco...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Shujiao, Li, Yan, Shi, Xuanren, Wang, Lei, Cai, Diya, Zhou, Jingfeng, Yu, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983225/ https://www.ncbi.nlm.nih.gov/pubmed/36864492 http://dx.doi.org/10.1186/s13148-023-01458-0

Ejemplares similares

Methylation-associated silencing of BASP1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia
por: Zhou, Lei, et al.
Publicado: (2018)

Epigenetic silencing of UBXN8 contributes to leukemogenesis in t(8;21) acute myeloid leukemia
por: Yang, Erna, et al.
Publicado: (2021)

Single-cell RNA sequencing of t(8;21) acute myeloid leukemia for risk prediction
por: Xiong, Qian, et al.
Publicado: (2020)

Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
por: Reikvam, Håkon, et al.
Publicado: (2011)

Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia
por: Purev, Enkhtsetseg, et al.
Publicado: (2014)

Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia
por: Pullarkat, Sheeja T., et al.
Publicado: (2009)

A case of acute myeloid leukemia-M2 with trisomy 4 in addition to t(8;21)
por: Trivedi, P. J., et al.
Publicado: (2008)

Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21)
por: Qin, Ya-Zhen, et al.
Publicado: (2018)

Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21)
por: Lu, Lianghao, et al.
Publicado: (2018)

High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia
por: Yang, Lu, et al.
Publicado: (2019)

Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML)
por: Wilde, Lindsay, et al.
Publicado: (2019)

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia
por: Qin, Ya-Zhen, et al.
Publicado: (2021)

JAK inhibitors suppress t(8;21) fusion protein-induced leukemia
por: Lo, Miao-Chia, et al.
Publicado: (2013)

Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia
por: Sood, Raman, et al.
Publicado: (2015)

ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation
por: Hartmann, Luise, et al.
Publicado: (2016)

Modelling t(8;21) acute myeloid leukaemia ‐ What have we learned?
por: Chin, Paulynn Suyin, et al.
Publicado: (2020)

t(8;21) Acute Myeloid Leukemia as a Paradigm for the Understanding of Leukemogenesis at the Level of Gene Regulation and Chromatin Programming
por: Kellaway, Sophie, et al.
Publicado: (2020)

Low IL7R Expression at Diagnosis Predicted Relapse in Adult Acute Myeloid Leukemia Patients With t(8;21)
por: Xu, Nan, et al.
Publicado: (2022)

High Expression of c-kit mRNA Predicts Unfavorable Outcome in Adult Patients with t(8;21) Acute Myeloid Leukemia
por: Gao, Xiaoning, et al.
Publicado: (2015)

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
por: Meyer, Tatjana, et al.
Publicado: (2019)

Successful Outcome of a Case of Acute Myeloid Leukemia with t(8;21)/AML-ETO Following Langerhans Cell Histiocytosis
por: Meng, Guangqiang, et al.
Publicado: (2019)

Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias
por: Su, Kuan-Wei, et al.
Publicado: (2021)

Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia
por: Huang, Sai, et al.
Publicado: (2016)

RNA demethylase ALKBH5 promotes tumorigenesis of t (8;21) acute myeloid leukemia via ITPA m6A modification
por: Li, Ran, et al.
Publicado: (2023)

POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature
por: Fortier, Julie M., et al.
Publicado: (2010)

Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
por: Ustun, Celalettin, et al.
Publicado: (2018)

PB1815: ADDITIONAL СYTOGENETIC ABNORMALITIES IN ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)
por: Zotova, Olena, et al.
Publicado: (2023)

A new inducible model for t(8;21) AML
por: Mulloy, James C
Publicado: (2013)

Acute Myeloid Leukemia with t(8;21)(q22;q22) and Trisomy 4: A Rare Occurrence in a Female Child
por: Kamran, Shawana, et al.
Publicado: (2019)

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Fan, Shuang, et al.
Publicado: (2022)

Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/RUNX1-RUNX1T1 Rearrangement
por: Tokunaga, Kenji, et al.
Publicado: (2017)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
por: Li, Zheng, et al.
Publicado: (2022)

MiR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death
por: Ding, Chao, et al.
Publicado: (2018)

Efficacy of a combination therapy targeting CDK4/6 and autophagy in a mouse xenograft model of t(8;21) acute myeloid leukemia
por: Matsuo, Hidemasa, et al.
Publicado: (2021)

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
por: Ruhnke, Leo, et al.
Publicado: (2023)

P437: EFFECTIVE IMMUNOTHERAPY OF PEDIATRIC T(8;21) ACUTE MYELOID LEUKEMIA BY REPURPOSING CD3XCD19 TARGETING BISPECIFIC ANTIBODIES
por: Wijnen, Noa, et al.
Publicado: (2023)

RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML
por: Loke, Justin, et al.
Publicado: (2017)

Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature
por: UZ, Burak, et al.
Publicado: (2013)

Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia
por: Issa, Hasan, et al.
Publicado: (2023)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v1ir4pbujbe3tqq1ehplg39o17